Tocilizumab-Associated Cecal Perforation in COVID-19 Pneumonia
- PMID: 34010161
- DOI: 10.1097/MJT.0000000000001334
Tocilizumab-Associated Cecal Perforation in COVID-19 Pneumonia
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
-
- Hart AR, Kennedy HJ, Stebbings WS, et al. How frequently do large bowel diverticula perforate? An incidence and cross-sectional study. Eur J Gastroenterol Hepatol. 2000;12:661–665.
-
- Xie F, Yun H, Bernatsky S, et al. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016;68:2612–2617.
-
- Vikse J, Henry BM. Tocilizumab in COVID-19: beware the risk of intestinal perforation. Int J Antimicrob Agents. 2020;56:106009.
-
- Rojo M, Cano-Valderrama O, Picazo S, et al. Gastrointestinal perforation after treatment with tocilizumab:an unexpected consequence of COVID-19 pandemic. Am Surgeon. 2020;86:565–566.
-
- Gonzálvez Guardiola P, Díez Ares J, Peris Tomás N, et al. Intestinal perforation in patient with COVID-19 infection treated with tocilizumab and corticosteroids. Report of a clinical case. Cirugia Espanola. 2020;2:156–157.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical